1. Home
  2. SKYE vs TLIH Comparison

SKYE vs TLIH Comparison

Compare SKYE & TLIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.94

Market Cap

20.0M

Sector

Health Care

ML Signal

HOLD

Logo Ten-League International Holdings Limited Ordinary Shares

TLIH

Ten-League International Holdings Limited Ordinary Shares

HOLD

Current Price

$5.73

Market Cap

17.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
TLIH
Founded
2012
1998
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0M
17.1M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
SKYE
TLIH
Price
$1.94
$5.73
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
549.5K
1.9K
Earning Date
05-08-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.34
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.22
52 Week High
$4.99
$5.96

Technical Indicators

Market Signals
Indicator
SKYE
TLIH
Relative Strength Index (RSI) 68.63 52.70
Support Level $0.66 $5.11
Resistance Level $2.32 $5.89
Average True Range (ATR) 0.15 0.25
MACD 0.09 -0.03
Stochastic Oscillator 74.33 82.46

Price Performance

Historical Comparison
SKYE
TLIH

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental, and provision of engineering consultancy services to port, construction, civil engineering, and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment, and port machinery. The company operates in Singapore and Other international countries.

Share on Social Networks: